Colorectal cancers differ in respect of PARP-1 protein expression

Polish Journal of Pathology

Volumn 63, Issue 2, 2012, Pages 87-92

  Sulzyc Bielicka, Violetta ^a   Domagala, Pawel ^a   Hybiak, Jolanta ^a   Majewicz Broda, Anna ^a   Safranow, Krzysztof ^a   Domagala, Wenancjusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Colorectal cancer; Colorectal cancer therapy; PARP inhibitor; PARP 1

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; COLORECTAL TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLY(ADP-RIBOSE) POLYMERASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864843538     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schreiber V, Dantzer F, Ame JC, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528.
2. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
3. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
4. Comen EA, Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park) 2010; 24: 55-62.
5. Basu B, Yap TA, Molife LR, et al. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol 2012; 24: 316-324.
6. Domagala P, Huzarski T, Lubinski J, et al. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011; 458: 55-64.
7. Domagala P, Huzarski T, Lubinski J, et al. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127: 861-869.
8. Nosho K, Yamamoto H, Mikami M, et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 2006; 42: 2374-2381.
9. SternMC, Conti DV, Siegmund KD, et al. DNA repair singlenucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2363-2372.
10. Solier S, Zhang YW, Ballestrero A, et al. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets 2012; 12: 356-371.
11. Geng L, Huehls AM, Wagner JM, et al. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 2011; 6: e28862.
12. IdogawaM, Yamada T, Honda K, et al. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/betacatenin complex. Gastroenterology 2005; 128: 1919-1936.
13. Domagala P, Lubinski J, DomagalaW. Iniparib in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 1780.
14. Chung GG, Kielhorn EP, Rimm DL. Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray. Clin Colorectal Cancer 2002; 1: 237-242.
15. Detre S, Saclani Jotti G, DowsettM. A "quickscore"method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876-878.
16. Barnett JC, Bean SM, Nakayama JM, et al. High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. Obstet Gynecol 2010; 115: 49-54.
17. Shimizu S, Nomura F, Tomonaga T, et al. Expression of poly-(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance. Oncol Rep 2004; 12: 821-825.
18. Klauschen F, vonWinterfeld M, Stenzinger A, et al. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology 2012 [Epub].
19. Csete B, Lengyel Z, Kadar Z, et al. Poly(adenosine diphosphateribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor. Pathol Oncol Res 2009; 15: 47-53.
20. Galia A, Calogero AE, Condorelli R, et al. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem 2012; 56: e9.
21. Lin L, Li J, Wang Y, et al. Relationship of PARG with PARP, VEGF and b-FGF in colorectal carcinoma. Chin J Cancer Res 2009; 21: 135-141.
22. Wang ZQ, Stingl L, Morrison C, et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997; 11: 2347-2358.
23. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997; 94: 7303-7307.
24. Ossovskaya V, Koo IC, Kaldjian EP, et al. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010; 1: 812-821.
25. Inbar-Rozensal D, Castiel A, Visochek L, et al. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res 2009; 11: R78.
26. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011; 71: 2632-2642.